TREATMENT OF B-CELL MALIGNANT NEW FORMATIONS USING AFUCHOSILED PROPAOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC MEDICINES

摘要

The invention relates to novel combined therapies using anti-CD19 antibodies for treating cancer B cells expressing CD19. One preferred method is the use of a pro-apoptotic anti-CD19 MAb or a pro-apoptotic humanized MAb optimized for Fc. In the methods of the present invention, certain anti-CD20 agents such as Rituxan or chemotherapy drugs such as vincristine can be used in combination therapy. The methods of the present invention reduce the levels of CD19-positive B, more specifically, in all subtypes of diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL).